Top

Published in:

29-04-2023 | Cardiomyopathy

Intermittent Hypoxic Preconditioning Plays a Cardioprotective Role in Doxorubicin-Induced Cardiomyopathy

Authors: Peter Galis, Linda Bartosova, Veronika Farkasova, Adrian Szobi, Csaba Horvath, Dominika Kovacova, Adriana Adameova, Tomas Rajtik

Published in: Cardiovascular Toxicology | Issue 5-6/2023

Abstract

Intermittent hypoxic preconditioning (IHP) is a well-established cardioprotective intervention in models of ischemia/reperfusion injury. Nevertheless, the significance of IHP in different cardiac pathologies remains elusive. In order to investigate the role of IHP and its effects on calcium-dependent signalization in HF, we employed a model of cardiomyopathy induced by doxorubicin (Dox), a widely used drug from the class of cardiotoxic antineoplastics, which was i.p. injected to Wistar rats (4 applications of 4 mg/kg/week). IHP-treated group was exposed to IHP for 2 weeks prior to Dox administration. IHP ameliorated Dox-induced reduction in cardiac output. Western blot analysis revealed increased expression of sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA2a) while the expression of hypoxia inducible factor (HIF)-1-α, which is a crucial regulator of hypoxia-inducible genes, was not changed. Animals administered with Dox had further decreased expression of TRPV1 and TRPV4 (transient receptor potential, vanilloid subtype) ion channels along with suppressed Ca²⁺/calmodulin-dependent protein kinase II (CaMKII) activation. In summary, IHP-mediated improvement in cardiac output in the model of Dox-induced cardiomyopathy is likely a result of increased SERCA2a expression which could implicate IHP as a potential protective intervention in Dox cardiomyopathy, however, further analysis of observed effects is still required.

Chung, W. B., & Youn, H. J. (2016). Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. The Korean Journal of Internal Medicine, 31(4), 625–633. https://doi.org/10.3904/kjim.2016.017CrossRefPubMedPubMedCentral

Volkova, M., & Russell, R., 3rd. (2011). Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Current Cardiology Reviews, 7(4), 214–220. https://doi.org/10.2174/157340311799960645CrossRefPubMedPubMedCentral

Rivera, E. (2003). Liposomal anthracyclines in metastatic breast cancer: Clinical update. The oncologist, 8(Suppl 2), 3–9. https://doi.org/10.1634/theoncologist.8-suppl_2-3CrossRefPubMed

Martins-Teixeira, M. B., & Carvalho, I. (2020). Antitumour anthracyclines: progress and perspectives. ChemMedChem, 15(11), 933–948. https://doi.org/10.1002/cmdc.202000131CrossRefPubMed

Shevchuk, O. O., Posokhova, E. A., Sakhno, L. A., & Nikolaev, V. G. (2012). Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity. Experimental Oncology, 34(4), 314–322.PubMed

Nebigil, C. G., & Désaubry, L. (2018). Updates in anthracycline-mediated cardiotoxicity. Frontiers in Pharmacology, 9, 1262. https://doi.org/10.3389/fphar.2018.01262CrossRefPubMedPubMedCentral

Sag, C. M., Köhler, A. C., Anderson, M. E., Backs, J., & Maier, L. S. (2011). CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. Journal of Molecular and Cellular Cardiology, 51(5), 749–759. https://doi.org/10.1016/j.yjmcc.2011.07.016CrossRefPubMedPubMedCentral

Llach, A., Mazevet, M., Mateo, P., Villejouvert, O., Ridoux, A., Rucker-Martin, C., Ribeiro, M., Fischmeister, R., Crozatier, B., Benitah, J. P., Morel, E., & Gómez, A. M. (2019). Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity. Journal of Molecular and Cellular Cardiology, 126, 129–139. https://doi.org/10.1016/j.yjmcc.2018.11.019CrossRefPubMed

Pecoraro, M., Rodríguez-Sinovas, A., Marzocco, S., Ciccarelli, M., Iaccarino, G., Pinto, A., & Popolo, A. (2017). Cardiotoxic effects of short-term doxorubicin administration: involvement of connexin 43 in calcium impairment. International Journal of Molecular Sciences, 18(10), 2121. https://doi.org/10.3390/ijms18102121CrossRefPubMedPubMedCentral

10.

Fernandez-Chas, M., Curtis, M. J., & Niederer, S. A. (2018). Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model. British Journal of Pharmacology, 175(5), 763–781. https://doi.org/10.1111/bph.14104CrossRefPubMedPubMedCentral

11.

Zhu, W., Reuter, S., & Field, L. J. (2019). Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity. Cardiovascular Research, 115(5), 960–965. https://doi.org/10.1093/cvr/cvy273CrossRefPubMed

12.

Kraft, J., Grille, W., Appelt, M., Hossfeld, D. K., Eichelbaum, M., Koslowski, B., Quabeck, K., Kuse, R., Büchner, T., & Hiddemann, W. (1990). Effects of verapamil on anthracycline-induced cardiomyopathy: Preliminary results of a prospective multicenter trial. Haematology and Blood Transfusion, 33, 566–570. https://doi.org/10.1007/978-3-642-74643-7_103CrossRefPubMed

13.

Milei, J., Marantz, A., Alé, J., Vazquez, A., & Buceta, J. E. (1987). Prevention of adriamycin-induced cardiotoxicity by prenylamine: A pilot double blind study. Cancer Drug Delivery, 4(2), 129–136. https://doi.org/10.1089/cdd.1987.4.129CrossRefPubMed

14.

Lu, M. J., Chen, Y. S., Huang, H. S., & Ma, M. C. (2014). Hypoxic preconditioning protects rat hearts against ischemia-reperfusion injury via the arachidonate12-lipoxygenase/transient receptor potential vanilloid 1 pathway. Basic Research in Cardiology, 109(4), 414. https://doi.org/10.1007/s00395-014-0414-0CrossRefPubMed

15.

Hu, K., Deng, W., Yang, J., Wei, Y., Wen, C., Li, X., Chen, Q., Ke, D., & Li, G. (2020). Intermittent hypoxia reduces infarct size in rats with acute myocardial infarction: A systematic review and meta-analysis. BMC Cardiovascular Disorders, 20(1), 422. https://doi.org/10.1186/s12872-020-01702-yCrossRefPubMedPubMedCentral

16.

Jarrard, C. P., Nagel, M. J., Stray-Gundersen, S., Tanaka, H., & Lalande, S. (2021). Hypoxic preconditioning attenuates ischemia-reperfusion injury in young healthy adults. Journal of Applied Physiology (Bethesda, Md: 1985), 130(3), 846–852. https://doi.org/10.1152/japplphysiol.00772.2020CrossRefPubMed

17.

Baumgarten, K. M., Gerstenblith, G., & Weiss, R. G. (1999). High extracellular K+ during hypoxic preconditioning episodes attenuates the post-ischemic contractile and ionic benefits of preconditioning. Journal of Molecular and Cellular Cardiology, 31(1), 203–213. https://doi.org/10.1006/jmcc.1998.0860CrossRefPubMed

18.

Liu, X., Xu, F., Fu, Y., Liu, F., Sun, S., & Wu, X. (2006). Calreticulin induces delayed cardioprotection through mitogen-activated protein kinases. Proteomics, 6(13), 3792–3800. https://doi.org/10.1002/pmic.200500906CrossRefPubMed

19.

Wu, X., Liu, X., Zhu, X., & Tang, C. (2007). Hypoxic preconditioning induces delayed cardioprotection through p38 MAPK-mediated calreticulin upregulation. Shock (Augusta, Ga), 27(5), 572–577. https://doi.org/10.1097/01.shk.0000246901.58068.a8CrossRefPubMed

20.

Cai, Z., Manalo, D. J., Wei, G., Rodriguez, E. R., Fox-Talbot, K., Lu, H., Zweier, J. L., & Semenza, G. L. (2003). Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation, 108(1), 79–85. https://doi.org/10.1161/01.CIR.0000078635.89229.8ACrossRefPubMed

21.

Tanaka, T., Yamaguchi, J., Shoji, K., & Nangaku, M. (2012). Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. The Journal of Biological Chemistry, 287(42), 34866–34882. https://doi.org/10.1074/jbc.M112.374587CrossRefPubMedPubMedCentral

22.

Graziani, S., Scorrano, L., & Pontarin, G. (2022). Transient exposure of endothelial cells to doxorubicin leads to long-lasting vascular endothelial growth factor receptor 2 downregulation. Cells, 11(2), 210. https://doi.org/10.3390/cells11020210CrossRefPubMedPubMedCentral

23.

Chiusa, M., Hool, S. L., Truetsch, P., Djafarzadeh, S., Jakob, S. M., Seifriz, F., Scherer, S. J., Suter, T. M., Zuppinger, C., & Zbinden, S. (2012). Cancer therapy modulates VEGF signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes. Journal of Molecular and Cellular Cardiology, 52(5), 1164–1175. https://doi.org/10.1016/j.yjmcc.2012.01.022CrossRefPubMed

24.

Huang, Y., Hickey, R. P., Yeh, J. L., Liu, D., Dadak, A., Young, L. H., Johnson, R. S., & Giordano, F. J. (2004). Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 18(10), 1138–1140. https://doi.org/10.1096/fj.04-1510fjeCrossRefPubMed

25.

Silter, M., Kögler, H., Zieseniss, A., Wilting, J., Schäfer, K., Toischer, K., Rokita, A. G., Breves, G., Maier, L. S., & Katschinski, D. M. (2010). Impaired Ca(2+)-handling in HIF-1alpha(+/-) mice as a consequence of pressure overload. Pflugers Archiv : European Journal of Physiology, 459(4), 569–577. https://doi.org/10.1007/s00424-009-0748-xCrossRefPubMed

26.

Rath, G., Saliez, J., Behets, G., Romero-Perez, M., Leon-Gomez, E., Bouzin, C., Vriens, J., Nilius, B., Feron, O., & Dessy, C. (2012). Vascular hypoxic preconditioning relies on TRPV4-dependent calcium influx and proper intercellular gap junctions communication. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2241–2249. https://doi.org/10.1161/ATVBAHA.112.252783CrossRefPubMed

27.

Hof, T., Chaigne, S., Récalde, A., Sallé, L., Brette, F., & Guinamard, R. (2019). Transient receptor potential channels in cardiac health and disease. Nature Reviews. Cardiology, 16(6), 344–360. https://doi.org/10.1038/s41569-018-0145-2CrossRefPubMed

28.

Kang, Y., Wang, W., Zhao, H., Qiao, Z., Shen, X., & He, B. (2017). Assessment of Subclinical Doxorubicin-induced Cardiotoxicity in a Rat Model by Speckle-Tracking Imaging. Arquivos brasileiros de cardiologia. https://doi.org/10.5935/abc.20170097CrossRefPubMedPubMedCentral

29.

Xi, L., Tekin, D., Gursoy, E., Salloum, F., Levasseur, J. E., & Kukreja, R. C. (2002). Evidence that NOS2 acts as a trigger and mediator of late preconditioning induced by acute systemic hypoxia. American Journal of Physiology. Heart and Circulatory Physiology, 283(1), 5–12. https://doi.org/10.1152/ajpheart.00920.2001CrossRef

30.

Szobi, A., Gonçalvesová, E., Varga, Z. V., Leszek, P., Kuśmierczyk, M., Hulman, M., Kyselovič, J., Ferdinandy, P., & Adameová, A. (2017). Analysis of necroptotic proteins in failing human hearts. Journal of Translational Medicine, 15(1), 86. https://doi.org/10.1186/s12967-017-1189-5CrossRefPubMedPubMedCentral

31.

Moritz, C. P. (2017). Tubulin or not tubulin: heading toward total protein staining as loading control in western blots. Proteomics. https://doi.org/10.1002/pmic.201600189CrossRefPubMed

32.

Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., Stanford, S. C., Teixeira, M. M., Wonnacott, S., & Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175(7), 987–993. https://doi.org/10.1111/bph.14153CrossRefPubMedPubMedCentral

33.

Rathod, N., Bak, J. J., Primeau, J. O., Fisher, M. E., Espinoza-Fonseca, L. M., Lemieux, M. J., & Young, H. S. (2021). Nothing regular about the regulins: distinct functional properties of SERCA transmembrane peptide regulatory subunits. International Journal of Molecular Sciences, 22(16), 8891. https://doi.org/10.3390/ijms22168891CrossRefPubMedPubMedCentral

34.

Chang, H. H., Hsu, S. P., & Chien, C. T. (2019). Intrarenal transplantation of hypoxic preconditioned mesenchymal stem cells improves glomerulonephritis through anti-oxidation, anti-ER stress, anti-inflammation, anti-apoptosis, and anti-autophagy. Antioxidants (Basel, Switzerland), 9(1), 2. https://doi.org/10.3390/antiox9010002CrossRefPubMed

35.

Chang, J. C., Lien, C. F., Lee, W. S., Chang, H. R., Hsu, Y. C., Luo, Y. P., Jeng, J. R., Hsieh, J. C., & Yang, K. T. (2019). Intermittent hypoxia prevents myocardial mitochondrial Ca2+ overload and cell death during ischemia/reperfusion: The role of reactive oxygen species. Cells, 8(6), 564. https://doi.org/10.3390/cells8060564CrossRefPubMedPubMedCentral

36.

Zhong, N., Zhang, Y., Zhu, H. F., & Zhou, Z. N. (2000). Intermittent hypoxia exposure prevents mtDNA deletion and mitochondrial structure damage produced by ischemia/reperfusion injury. Sheng li xue bao: Acta physiologica Sinica, 52(5), 375–380.PubMed

37.

Wang, Z., & Si, L. Y. (2013). Hypoxia-inducible factor-1α and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats. Upsala Journal of Medical Sciences, 118(2), 65–74. https://doi.org/10.3109/03009734.2013.766914CrossRefPubMedPubMedCentral

38.

Semenza, G. L. (2014). Hypoxia-inducible factor 1 and cardiovascular disease. Annual Review of Physiology, 76, 39–56. https://doi.org/10.1146/annurev-physiol-021113-170322CrossRefPubMed

39.

Li, J., Li, C., Yuan, W., Wu, J., Li, J., Li, Z., & Zhao, Y. (2021). Targeted temperature management suppresses hypoxia-inducible factor-1α and vascular endothelial growth factor expression in a pig model of cardiac arrest. Neurocritical caRe, 35(2), 379–388. https://doi.org/10.1007/s12028-020-01166-0CrossRefPubMedPubMedCentral

40.

Xie, H. C., Li, J. G., & He, J. P. (2017). Differential responsiveness in VEGF receptor subtypes to hypoxic stress in various tissues of plateau animals. Physiological Research, 66(2), 357–362. https://doi.org/10.33549/physiolres.933408CrossRefPubMed

41.

Lin, J. S., Chen, Y. S., Chiang, H. S., & Ma, M. C. (2008). Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: Role of erythropoietin on progenitor cell mobilization. The Journal of Physiology, 586(23), 5757–5769. https://doi.org/10.1113/jphysiol.2008.160887CrossRefPubMedPubMedCentral

42.

Simůnek, T., Sterba, M., Holecková, M., Kaplanová, J., Klimtová, I., Adamcová, M., Gersl, V., & Hrdina, R. (2005). Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals : An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine, 18(2), 163–169. https://doi.org/10.1007/s10534-004-4491-7CrossRefPubMed

43.

Babick, A. P., Cantor, E. J., Babick, J. T., Takeda, N., Dhalla, N. S., & Netticadan, T. (2004). Cardiac contractile dysfunction in J2N-k cardiomyopathic hamsters is associated with impaired SR function and regulation. American Journal of Physiology. Cell Physiology, 287(5), C1202–C1208. https://doi.org/10.1152/ajpcell.00155.2004CrossRefPubMed

44.

Ji, Y., Lalli, M. J., Babu, G. J., Xu, Y., Kirkpatrick, D. L., Liu, L. H., Chiamvimonvat, N., Walsh, R. A., Shull, G. E., & Periasamy, M. (2000). Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. The Journal of Biological Chemistry, 275(48), 38073–38080. https://doi.org/10.1074/jbc.M004804200CrossRefPubMed

45.

Ezzitouny, M., Roselló-Lletí, E., Portolés, M., Sánchez-Lázaro, I., Arnau-Vives, M. Á., Tarazón, E., Gil-Cayuela, C., Lozano-Edo, S., López-Vilella, R., Almenar-Bonet, L., & Martínez-Dolz, L. (2021). Value of SERCA2a as a biomarker for the identification of patients with heart failure requiring circulatory support. Journal of Personalized Medicine, 11(11), 1122. https://doi.org/10.3390/jpm11111122CrossRefPubMedPubMedCentral

46.

Samuel, T. J., Rosenberry, R. P., Lee, S., & Pan, Z. (2018). Correcting calcium dysregulation in chronic heart failure using SERCA2a gene therapy. International Journal of Molecular Sciences, 19(4), 1086. https://doi.org/10.3390/ijms19041086CrossRefPubMedPubMedCentral

47.

Lenčová-Popelová, O., Jirkovský, E., Mazurová, Y., Lenčo, J., Adamcová, M., Šimůnek, T., Geršl, V., & Štěrba, M. (2014). Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One, 9(5), e96055. https://doi.org/10.1371/journal.pone.0096055CrossRefPubMedPubMedCentral

48.

Matsuda, N., Morgan, K. G., & Sellke, F. W. (1999). Preconditioning improves cardioplegia-related coronary microvascular smooth muscle hypercontractility: Role of KATP channels. The Journal of Thoracic and Cardiovascular Surgery, 118(3), 438–445. https://doi.org/10.1016/S0022-5223(99)70180-7CrossRefPubMed

49.

Westberg, J. A., Serlachius, M., Lankila, P., & Andersson, L. C. (2007). Hypoxic preconditioning induces elevated expression of stanniocalcin-1 in the heart. American Journal of Physiology. Heart and Circulatory Physiology, 293(3), H1766–H1771. https://doi.org/10.1152/ajpheart.00017.2007CrossRefPubMed

50.

Chen, R. C., Sun, G. B., Ye, J. X., Wang, J., Zhang, M. D., & Sun, X. B. (2017). Salvianolic acid B attenuates doxorubicin-induced ER stress by inhibiting TRPC3 and TRPC6 mediated Ca2+ overload in rat cardiomyocytes. Toxicology Letters, 276, 21–30. https://doi.org/10.1016/j.toxlet.2017.04.010CrossRefPubMed

51.

Takada, A., Miki, T., Kuno, A., Kouzu, H., Sunaga, D., Itoh, T., Tanno, M., Yano, T., Sato, T., Ishikawa, S., & Miura, T. (2012). Role of ER stress in ventricular contractile dysfunction in type 2 diabetes. PLoS One, 7(6), e39893. https://doi.org/10.1371/journal.pone.0039893CrossRefPubMedPubMedCentral

52.

Wu, X. D., Zhang, Z. Y., Sun, S., Li, Y. Z., Wang, X. R., Zhu, X. Q., Li, W. H., & Liu, X. H. (2013). Hypoxic preconditioning protects microvascular endothelial cells against hypoxia/reoxygenation injury by attenuating endoplasmic reticulum stress. Apoptosis : An International Journal on Programmed Cell Death, 18(1), 85–98. https://doi.org/10.1007/s10495-012-0766-6CrossRefPubMed

53.

Wang, J., Wu, Y., Yuan, F., Liu, Y., Wang, X., Cao, F., Zhang, Y., & Wang, S. (2016). Chronic intermittent hypobaric hypoxia attenuates radiation induced heart damage in rats. Life Sciences, 160, 57–63. https://doi.org/10.1016/j.lfs.2016.07.002CrossRefPubMed

54.

Hamstra, S. I., Whitley, K. C., Baranowski, R. W., Kurgan, N., Braun, J. L., Messner, H. N., & Fajardo, V. A. (2020). The role of phospholamban and GSK3 in regulating rodent cardiac SERCA function. American Journal of Physiology. Cell Physiology, 319(4), C694–C699. https://doi.org/10.1152/ajpcell.00318.2020CrossRefPubMed

55.

Tscheschner, H., Meinhardt, E., Schlegel, P., Jungmann, A., Lehmann, L. H., Müller, O. J., Most, P., Katus, H. A., & Raake, P. W. (2019). CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression. PLoS One, 14(4), e0215992. https://doi.org/10.1371/journal.pone.0215992CrossRefPubMedPubMedCentral

56.

Anderson, M. E., Brown, J. H., & Bers, D. M. (2011). CaMKII in myocardial hypertrophy and heart failure. Journal of Molecular and Cellular Cardiology, 51(4), 468–473. https://doi.org/10.1016/j.yjmcc.2011.01.012CrossRefPubMedPubMedCentral

57.

Zhang, T., Zhang, Y., Cui, M., Jin, L., Wang, Y., Lv, F., Liu, Y., Zheng, W., Shang, H., Zhang, J., Zhang, M., Wu, H., Guo, J., Zhang, X., Hu, X., Cao, C. M., & Xiao, R. P. (2016). CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nature Medicine, 22(2), 175–182. https://doi.org/10.1038/nm.4017CrossRefPubMed

58.

Rajtik, T., Carnicka, S., Szobi, A., Giricz, Z., O-Uchi, J., VHassova, Svec, P., Ferdinandy, P., Ravingerova, T., & Adameova, A. (2016). Oxidative activation of CaMKIIδ in acute myocardial ischemia/reperfusion injury: A role of angiotensin AT1 receptor-NOX2 signaling axis. European Journal of Pharmacology, 771, 114–122. https://doi.org/10.1016/j.ejphar.2015.12.024CrossRefPubMed

59.

Szobi, A., Rajtik, T., Carnicka, S., Ravingerova, T., & Adameova, A. (2014). Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: Effects on programmed necrotic and apoptotic cell death. Molecular and Cellular Biochemistry, 388(1–2), 269–276. https://doi.org/10.1007/s11010-013-1918-xCrossRefPubMed

60.

Koncsos, G., Varga, Z. V., Baranyai, T., Boengler, K., Rohrbach, S., Li, L., Schlüter, K. D., Schreckenberg, R., Radovits, T., Oláh, A., Mátyás, C., Lux, Á., Al-Khrasani, M., Komlódi, T., Bukosza, N., Máthé, D., Deres, L., Barteková, M., Rajtík, T., Adameová, A., … Ferdinandy, P. (2016). Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. American journal of physiology. Heart and circulatory physiology, 311(4), H927–H943. https://doi.org/10.1152/ajpheart.00049.2016.

61.

Woolums, B. M., McCray, B. A., Sung, H., Tabuchi, M., Sullivan, J. M., Ruppell, K. T., Yang, Y., Mamah, C., Aisenberg, W. H., Saavedra-Rivera, P. C., Larin, B. S., Lau, A. R., Robinson, D. N., Xiang, Y., Wu, M. N., Sumner, C. J., & Lloyd, T. E. (2020). TRPV4 disrupts mitochondrial transport and causes axonal degeneration via a CaMKII-dependent elevation of intracellular Ca2. Nature Communications, 11(1), 2679. https://doi.org/10.1038/s41467-020-16411-5CrossRefPubMedPubMedCentral

62.

Zhang, S., Lu, K., Yang, S., Wu, Y., Liao, J., Lu, Y., Wu, Q., Zhao, N., Dong, Q., Chen, L., & Du, Y. (2021). Activation of transient receptor potential vanilloid 4 exacerbates myocardial ischemia-reperfusion injury via JNK-CaMKII phosphorylation pathway in isolated mice hearts. Cell Calcium, 100, 102483. https://doi.org/10.1016/j.ceca.2021.102483CrossRefPubMed

63.

Adapala, R. K., Kanugula, A. K., Paruchuri, S., Chilian, W. M., & Thodeti, C. K. (2020). TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation. Basic Research in Cardiology, 115(2), 14. https://doi.org/10.1007/s00395-020-0775-5CrossRefPubMedPubMedCentral

64.

Horton, J. S., Buckley, C. L., & Stokes, A. J. (2013). Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice. Channels (Austin, Tex.), 7(1), 17–22. https://doi.org/10.4161/chan.23006CrossRefPubMed

65.

Iwata, Y., Wakabayashi, S., Ito, S., & Kitakaze, M. (2020). Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models. Laboratory Investigation; A Journal of Technical Methods and Pathology, 100(2), 324–337. https://doi.org/10.1038/s41374-019-0363-1CrossRefPubMed

66.

Zhang, Q., Qi, H., Cao, Y., Shi, P., Song, C., Ba, L., Chen, Y., Gao, J., Li, S., Li, B., & Sun, H. (2018). Activation of transient receptor potential vanilloid 3 channel (TRPV3) aggravated pathological cardiac hypertrophy via calcineurin/NFATc3 pathway in rats. Journal of Cellular and Molecular Medicine, 22(12), 6055–6067. https://doi.org/10.1111/jcmm.13880CrossRefPubMedPubMedCentral

Title: Intermittent Hypoxic Preconditioning Plays a Cardioprotective Role in Doxorubicin-Induced Cardiomyopathy
Authors: Peter Galis
Linda Bartosova
Veronika Farkasova
Adrian Szobi
Csaba Horvath
Dominika Kovacova
Adriana Adameova
Tomas Rajtik
Publication date: 29-04-2023
Publisher: Springer US
Keyword: Cardiomyopathy
Published in: Cardiovascular Toxicology / Issue 5-6/2023
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09793-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intermittent Hypoxic Preconditioning Plays a Cardioprotective Role in Doxorubicin-Induced Cardiomyopathy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2023

Cardiovascular Harmful Effects of Recommended Daily Doses (13 µg/kg/day), Tolerable Upper Intake Doses (0.14 mg/kg/day) and Twice the Tolerable Doses (0.28 mg/kg/day) of Copper

Electropharmacological Characterization of Licorice Using the Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Sheets and the Chronic Atrioventricular Block Dogs

The Acute Effect of Trimethylamine-N-Oxide on Vascular Function, Oxidative Stress, and Inflammation in Rat Aortic Rings

Protective Role of Short-term Aerobic Exercise Against Zinc Oxide Nanoparticles-Induced Cardiac Oxidative Stress Via Possible Changes of Apelin, Angiotensin II/Angiotensin II Type I Signalling Pathway

Retraction Note: Alpha-Lipoic Acid Protects Against Doxorubicin-Induced Cardiotoxicity by Regulating Pyruvate Dehydrogenase Kinase 4

Retraction Note: Ergosterol Attenuates Isoproterenol-Induced Myocardial Cardiotoxicity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page